The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...
The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...
The Biomarkers Market is anticipated to expand at a rapid pace due to the increasing demand for personalized medicine, rising prevalence of chronic and...
Nonprofit health plan and Gemini Health deliver real-time notifications, allowing members to compare prescription drug prices, find lower-cost alternatives
OAKLAND, Calif., Aug. 6, 2025...
NEW YORK and NEW ORLEANS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...
The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...
HARLEM, N.Y., Aug. 5, 2025 /PRNewswire/ -- Legionnaires' disease lawyer Jory Lange and prominent Manhattan attorney Scott Harford have been retained to investigate an...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, and nutrients. Discover insights, identified consumer groups, and actionable strategies for food companies.
Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, and nutrients. Discover insights, identified consumer groups, and actionable strategies for food companies.
GUANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock...
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...